Maitri Enterprises Ltd
Incorporated in 1991, Maitri Enterprises Ltd trades in Pharmaceutical & Medical Goods.[1]
- Market Cap ₹ 19.2 Cr.
- Current Price ₹ 43.6
- High / Low ₹ 44.7 / 22.1
- Stock P/E 23.4
- Book Value ₹ 14.7
- Dividend Yield 0.00 %
- ROCE 15.8 %
- ROE 13.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Debtor days have improved from 54.1 to 28.2 days.
Cons
- Stock is trading at 2.97 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.1% over last 3 years.
- Earnings include an other income of Rs.0.51 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.55 | 0.32 | 0.64 | 0.69 | 6.16 | 6.66 | 4.54 | 12.58 | 9.87 | 18.35 | 28.62 | 32.19 | |
| 0.63 | 0.41 | 0.71 | 0.73 | 6.17 | 6.67 | 4.45 | 12.17 | 9.28 | 17.89 | 26.35 | 30.83 | |
| Operating Profit | -0.08 | -0.09 | -0.07 | -0.04 | -0.01 | -0.01 | 0.09 | 0.41 | 0.59 | 0.46 | 2.27 | 1.36 |
| OPM % | -14.55% | -28.12% | -10.94% | -5.80% | -0.16% | -0.15% | 1.98% | 3.26% | 5.98% | 2.51% | 7.93% | 4.22% |
| 0.11 | 0.11 | 0.10 | 0.10 | 0.08 | 0.27 | 0.08 | 0.03 | 0.03 | 0.26 | -1.01 | 0.51 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.07 | 0.09 | 0.55 | 0.73 | 0.66 |
| Depreciation | 0.02 | 0.02 | 0.01 | 0.01 | 0.03 | 0.04 | 0.05 | 0.07 | 0.06 | 0.05 | 0.07 | 0.07 |
| Profit before tax | 0.01 | 0.00 | 0.02 | 0.04 | 0.02 | 0.21 | 0.10 | 0.30 | 0.47 | 0.12 | 0.46 | 1.14 |
| Tax % | 0.00% | 0.00% | 25.00% | 50.00% | 23.81% | 40.00% | 26.67% | 29.79% | 33.33% | 34.78% | 28.07% | |
| 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.16 | 0.07 | 0.22 | 0.34 | 0.08 | 0.30 | 0.82 | |
| EPS in Rs | 0.02 | 0.00 | 0.11 | 0.11 | 0.05 | 0.84 | 0.37 | 0.50 | 0.77 | 0.18 | 0.68 | 1.86 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 48% |
| 3 Years: | 48% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 34% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 26% |
| 1 Year: | 76% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.75 | 1.90 | 1.90 | 1.90 | 1.90 | 1.90 | 1.90 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Reserves | -2.80 | -0.14 | -0.13 | -0.10 | -0.09 | 0.07 | 0.14 | 0.56 | 0.90 | 0.98 | 1.29 | 2.07 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.40 | 1.77 | 2.41 | 9.99 | 6.30 | 4.30 | |
| 0.18 | 0.11 | 0.40 | 0.26 | 3.28 | 2.59 | 3.96 | 4.91 | 5.76 | 6.29 | 4.46 | 4.50 | |
| Total Liabilities | 2.13 | 1.87 | 2.17 | 2.06 | 5.09 | 4.67 | 6.40 | 11.64 | 13.47 | 21.66 | 16.45 | 15.27 |
| 0.09 | 0.08 | 0.06 | 0.06 | 0.13 | 0.10 | 0.22 | 0.18 | 0.15 | 0.16 | 0.18 | 0.33 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.37 | 3.37 | 7.02 | 6.83 | 6.83 |
| 2.04 | 1.79 | 2.11 | 2.00 | 4.96 | 4.57 | 6.18 | 8.09 | 9.95 | 14.48 | 9.44 | 8.11 | |
| Total Assets | 2.13 | 1.87 | 2.17 | 2.06 | 5.09 | 4.67 | 6.40 | 11.64 | 13.47 | 21.66 | 16.45 | 15.27 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.02 | -0.22 | 0.00 | 0.17 | 0.64 | -0.17 | -0.62 | -0.20 | -1.70 | 2.60 | 1.56 | |
| 0.00 | 0.00 | 0.00 | -0.01 | -0.08 | -0.62 | -0.06 | -3.39 | -0.26 | -5.24 | 1.78 | 1.07 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.27 | 3.99 | 0.55 | 7.03 | -4.39 | -2.65 | |
| Net Cash Flow | 0.00 | 0.02 | -0.22 | -0.02 | 0.10 | 0.01 | 0.04 | -0.01 | 0.09 | 0.09 | -0.02 | -0.03 |
| Free Cash Flow | 0.00 | 0.02 | -0.22 | -0.01 | 0.09 | 0.63 | -0.33 | -0.64 | -0.23 | -1.76 | 2.52 | 1.33 |
| CFO/OP | 0% | -33% | 300% | 0% | -1,500% | -6,900% | -144% | -132% | -12% | -335% | 123% | 124% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106.18 | 433.44 | 250.94 | 333.26 | 81.77 | 60.29 | 126.22 | 67.60 | 68.78 | 104.63 | 29.33 | 28.23 |
| Inventory Days | 419.75 | 580.68 | 423.07 | 304.17 | 123.56 | 132.35 | 318.36 | 140.85 | 273.63 | 129.31 | 83.97 | 71.82 |
| Days Payable | 155.12 | 182.50 | 331.82 | 174.90 | 203.62 | 155.50 | 397.44 | 145.93 | 242.72 | 124.24 | 74.98 | 69.04 |
| Cash Conversion Cycle | 370.81 | 831.62 | 342.19 | 462.53 | 1.71 | 37.14 | 47.14 | 62.52 | 99.70 | 109.69 | 38.32 | 31.01 |
| Working Capital Days | 1,101.64 | 1,882.03 | 941.02 | 893.99 | 67.55 | 44.39 | 77.98 | 56.00 | 96.15 | 95.28 | 2.55 | 6.58 |
| ROCE % | 0.51% | 0.00% | 1.13% | 2.80% | 2.22% | 11.31% | 5.31% | 8.07% | 7.76% | 5.81% | 16.08% | 15.82% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trade Receivables Turnover Ratio |
|
|||||||||
| Revenue Contribution - Pharmaceutical Goods Percentage |
||||||||||
| Revenue from Clearing & Forwarding Services INR Lakhs |
||||||||||
| Revenue from Infrastructure / Works Contract Services INR Lakhs |
||||||||||
| Net Capital Turnover Ratio Ratio |
||||||||||
| Number of Permanent Employees Number |
||||||||||
| Number of Pharma Distribution Rights (Companies) Number |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper Advertisement for an Audited Standalone & Consolidated Financial Result for the Quarter and Year Ended on March 31, 2026.
-
Board Meeting Outcome for Meeting Of The Board
28 May - FY26 audited standalone and consolidated results approved; consolidated audit qualified on Rs156.64 lakh subsidiary receivables.
-
Results-Financial Results For Period Ended 31St March 2026
28 May - Board approved FY26 audited standalone and consolidated results; consolidated audit qualified over subsidiary receivables.
-
Board Meeting Intimation for Intimation Of 2Nd Board Meeting Of F.Y. 2026-27 To Be Held On Friday, May 28, 2026.
25 May - Board meeting on May 28, 2026 to approve audited results for quarter and year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
30 Apr - Uddesh Jain resigned as Company Secretary and Compliance Officer effective 30 April 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
MEL is engaged in trading of Pharmaceutical & Medical Goods in Gujarat. This includes sale of service by way of works contract. Apart from this, the co. is also in the business of Infra
structure and Real Estate.